Asklepios BioPharma Launches New Biotech Actus Therapeutics Post author:Sam Post published:December 14, 2017 Post category:BioPharma Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics. Source: BioSpace You Might Also Like This Boston Biotech Gets $57.5 Million Upfront, $2.1 Billion Commitment From Drug Giant AstraZeneca PLC May 2, 2017 MolecularMD Announces Partnership With To Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services September 28, 2017 BioLineRx To Report Annual 2016 Results On March 23, 2017 March 15, 2017
This Boston Biotech Gets $57.5 Million Upfront, $2.1 Billion Commitment From Drug Giant AstraZeneca PLC May 2, 2017
MolecularMD Announces Partnership With To Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services September 28, 2017
